The Sept 22 event will spotlight the science behind Sensorion’s lead gene therapy candidate, the GJB2-related hearing loss patient population, and the design of the HearConnex clinical trial.
Sensorion, a clinical-stage biotechnology company focused on developing therapies to restore and treat hearing loss, has announced registration and connection details for its SENS-601 Program Day, scheduled for Sept 22, 2026.
The event will be dedicated entirely to SENS-601 (GJB2-GT), the company’s lead gene therapy program targeting hearing loss caused by mutations in the GJB2 gene. The program day is intended to give investors, clinicians, and researchers a detailed look at the underlying science, the relevant patient population, and the design and endpoints of the HearConnex trial.
Expert Speakers to Address Science and Clinical Design
The program day will bring together members of Sensorion’s management team alongside two external speakers: Prof Christine Petit of the Institut Pasteur – Institut de l’Audition / Institut reConnect, and Dr Sharon Cushing of The Hospital for Sick Children in Toronto, who serves as coordinating investigator for HearConnex.
Full event details, including the agenda, are available on Sensorion’s website at www.sensorion.com.
About SENS-601 and the HearConnex Trial
SENS-601 is Sensorion’s lead gene therapy program, developed in the framework of a broad strategic collaboration with the Institut Pasteur focused on the genetics of hearing. The therapy targets hearing loss related to mutations in the GJB2 gene, with the aim of addressing significant hearing loss segments in both adults and children.
GJB2 mutations are among the most common genetic causes of congenital hearing loss, making the program of particular relevance to audiologists and hearing healthcare professionals involved in the care of patients with hereditary hearing impairment. The Hearing Review has previously covered Sensorion’s regulatory progress in advancing the HearConnex trial, including French regulatory approval to initiate the study.
Pipeline Context
Beyond its gene therapy program, Sensorion’s pipeline includes a clinical-stage small molecule program, SENS-401 (Arazasetron), studied for the treatment and prevention of hearing loss disorders across three Phase II proof-of-concept clinical studies: cisplatin-induced ototoxicity (CIO), for which analysis was completed in Q1 2026; residual hearing preservation in patients scheduled for cochlear implantation, conducted in partnership with Cochlear Limited and completed in 2024; and sudden sensorineural hearing loss (SSNHL), for which a Phase II study was completed in 2022.
The Hearing Review has previously reported on Sensorion’s broader gene therapy pipeline updates and the company’s SSNHL drug trial results.
